Olvi-vec (olvimulogene nanivacirepvec) is Genelux's proprietary, advanced oncolytic vaccinia viral immunotherapy candidate designed to target and destroy solid tumors selectively. Engineered to replicate within cancer cells while stimulating a robust systemic anti-tumor immune response, it has been evaluated in multiple clinical trials across various refractory cancer indications, including ovarian and lung tumors.